Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events is a research paper published in Cancer (2021). On theSindex it has a DataRank of 0.266. It has been cited 4 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0.0246
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 2 citers.
National Cancer Institute
Grant: U01CA233169
NCI NIH HHS
Grant: UG1 CA232760
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: UG1 CA189828
NCI NIH HHS
Grant: UG1 CA233320
NCI NIH HHS
Grant: UG1 CA233160
NCI NIH HHS
Grant: UG1 CA233331
NCI NIH HHS
Grant: U10 CA081851
NCI NIH HHS
Grant: U10 CA180794
MeSH Terms
Keywords